Urokinase-type plasminogen activator (uPA) with its receptor (uPAR) displays crucial role in tumor progression and metastasis, and PAI-1 is the predominant endogenous inhibitor of uPA (Thorsen et al., 1988). The gene discussed is PLAU; the disease is neoplasm.